Agilent Technologies Inc. has announced that scientists using an Agilent custom-designed comparative genomic hybridization (CGH) array have sequenced the entire gene map of a Korean male. An ...
Comparative genomic hybridization (CGH) was developed to identify pathogenic DNA copy-number changes (e.g., duplications, deletions) on a genome-wide scale, and to map these changes to genomic ...
“A large market has emerged for the use of microarrays in novel applications, such as CGH, ChIP-chip, and DNA methylation,“ Nuwaysir adds. “Traditional gene-expression microarray experiments offer a ...
Comparative genomic hybridization using arrays of genomic cosmid, P1 and BAC clones (array CGH) provides quantitative copy number data over a wide dynamic range with resolution determined solely by ...
Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma Genomic losses were ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include a full text component.
Comparative genomic hybridization (CGH) has been used for a genome-wide screening of genetic imbalances in tumours. As CGH to chromosomes is technically difficult and yields only limited resolution, ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback